Ribo Submitted Application for New Weight Loss Drug
The drug candidate RBD3133, which targets the INHBE gene, is heading into human safety trials for obesity.
Updated on Oct. 8, 2026 in Weight Loss
Live Poll
Do you believe the development of new obesity medications is moving in the right direction?
Ribo has filed a Phase 1 clinical trial application in the European Union to test the experimental drug RBD3133. This trial marks the first human assessment of the siRNA therapeutic in people living with overweight or obesity.
Why it matters
Human genetic research has linked loss-of-function variants in the INHBE gene to healthier fat distribution and metabolic profiles. This trial aims to determine if silencing this gene can replicate those benefits to address the global need for new obesity treatments.
The upcoming Phase 1, randomized, placebo-controlled trial will conduct the first human assessment of RBD3133. The study aims to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics in individuals with overweight or obesity.
The players
Ribo
A biotechnology company based in Suzhou, China, specializing in siRNA therapeutics for various metabolic conditions.
Ribocure Pharmaceuticals AB
The Mölndal, Sweden-based subsidiary of Ribo responsible for the development of siRNA drug candidates.
The details
RBD3133 is an siRNA therapeutic designed to be administered subcutaneously. It works by selectively silencing the INHBE gene, which encodes the protein activin E. By inhibiting this protein, researchers hope to influence fat distribution and metabolic health.
Timeline
Ribo announced the successful submission of the clinical trial application on October 8, 2026.
Health Landscape
The development of RBD3133 reflects a shift toward targeting specific genetic pathways to manage obesity, moving beyond traditional appetite suppressants. This trial follows the broader trend of applying RNA interference technology to address common metabolic health conditions.
Because this study is in an early, preliminary phase, it does not currently change any existing treatment options for obesity. If you are interested in new developments for metabolic health, it is worth discussing the potential role of genetic therapies with your physician.
The takeaway
This drug candidate represents a new genetic approach to metabolic health that is currently being evaluated for safety in human subjects. For those managing obesity, the best path remains ongoing monitoring and personalized guidance from a medical professional.
Further reading
Learn more about the latest research in our Weight Loss section.
Live Poll
Do you believe the development of new obesity medications is moving in the right direction?
